"Amgen's Repatha Cuts Heart Attack Risk by 25% in Key Clinical Trial"

Amgens Repatha has proven to cut the risk of major cardiovascular disease events by 25% in high-risk adults, marking a significant advancement in preventive healthcare.

• In the Phase 3 VESALIUS-CV clinical trial, involving over 12,000 patients with atherosclerosis or diabetes, Repatha reduced the risk of myocardial infarction and stroke by 25%.
• The trial results indicate that adding Repatha to statin or other cholesterol-lowering treatments significantly lowers the risk of coronary heart disease death and ischemic stroke.
• Amgens Repatha works by targeting the PCSK9 protein, effectively lowering low-density lipoprotein levels, which are crucial in managing cardiovascular disease.